Revvity (RVTY)
Health Care · Health Science Solutions and Diagnostic Technologies
Revvity is a leading health science technology company providing integrated workflows and reagents spanning drug discovery, development, and diagnostic applications across life sciences and diagnostics markets.
What Revvity does
Revvity provides health science solutions, technologies, and services that facilitate complete workflows from discovery to development, and diagnosis to cure. The company operates through two segments: Life Sciences, offering reagents, imaging solutions, assay kits, and gene modulation technologies for pharmaceutical, biotech, and academic research; and Diagnostics, delivering screening and diagnostic solutions. With approximately 11,000 employees and presence in over 160 countries, Revvity serves pharmaceutical, biotech, contract research organizations, and academic institutions globally.
Themes: ["Drug discovery and development","Translational multi-omics","Biomarker identification","Gene therapy and cell engineering","Precision medicine diagnostics","Life sciences research tools","Immunoassays and immunology","AI and informatics","Oncology research","Neuroscience research"]
Fundamentals
- Price$112.95 as of 2026-07-09 close
- Market cap$12.6B as of 2026-07-10
- 1-year return+12.8% as of 2026-07-09 close
- P/E52.40 as of 2026-07-10
- Net margin+8.3% as of 2026-07-10
- Gross margin+54.3% as of 2026-07-10
- ROE+3.3% as of 2026-07-10
- Debt / equity0.45 as of 2026-07-10
- Revenue growth (YoY)+4.8% as of 2026-07-10
- Revenue CAGR (3y)-9.3% SEC XBRL
- Beta1.07 as of 2026-07-10
Dividend: yield +0.2%; 3-year non-decreasing per-share dividend streak (SEC XBRL).
Key risks (from latest filing)
["Revenue concentration risk from pharmaceutical and biotech customer base dependency for drug discovery and development workflows","Acquisition integration and technology integration challenges as growth strategy relies on M&A for expanding offerings","Foreign currency translation exposure with significant international operations across 160+ countries impacting reported results"]
Competitors & peers
- Thermo Fisher Scientific (TMPL)
- Danaher Corporation (DHR)
- Waters Corporation (WAT)
- Avantor (AVTR)
- Bio-Rad Laboratories (BIO)
- PerkinElmer (PKI)
- Shimadzu Scientific Instruments
- Bruker Corporation
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.